Navigation Links
Disease and Therapy Review: Bladder Cancer Now Available at ReportsandReports
Date:6/29/2010

DALLAS, June 29, 2010 /PRNewswire/ -- ReportsandReports announces it will carry the Disease and Therapy Review: Bladder Cancer Market Research Report in its Store

Browse the complete Report on: http://www.reportsandreports.com/market-reports/disease-and-therapy-review-bl adder-cancer/

The Bladder Cancer Disease and Therapy Review provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the cancer market, as well as sales of leading drugs and therapies are provided.

Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data s
'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
2. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
3. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
6. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
7. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
8. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
9. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
10. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
11. AAAAI: Call for Entries: Have You Written a Story on Allergic Disease? Win $1000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... & Budapest, Hungary (PRWEB) April 30, 2015 ... web-based electronic lab notebook with integrated protocols and ... providing chemistry software solutions and consulting services for ... to the development of Labguru’s newest feature: chemical ... of deep domain features for biologists, bio-chemists, and ...
(Date:4/30/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... contract R&D services provider, today announced that its board ... dated April 29, 2015, from a consortium (the "Consortium") ... founder, chairman and chief executive officer of the Company, ... a transaction (the "Transaction") involving the acquisition of all ...
(Date:4/30/2015)... Sterlitech is proud to offer ... PX, PY, and PZ Polyacrylonotrile (PAN) membranes , ... Designed to be ideal for oil removal in ... critical process requirements where the presence of oils ... regulations on industrial wastewater discharge and quality requirements ...
(Date:4/29/2015)... N.J. , April 29, 2015 Cambrex Corporation ... results will be released on Friday, May 1, 2015 before ... The Company will host a conference call to ... When: , Friday, May 1, ... , 1-888-468-2440 for U.S.1-719-325-2454 for International  Passcode:  7993632 ...
Breaking Biology Technology:Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Sterlitech Offers New Ultrafiltration Membranes 2
... INDIANAPOLIS, Oct. 30, 2009 Amylin Pharmaceuticals, Inc., (Nasdaq: ... ) today announced that the U.S. Food and Drug Administration ... BYETTA is now approved for use as a stand-alone medication ... in adults with type 2 diabetes. Previously, it was approved ...
... Calif., Oct. 30 ThermoGenesis Corp. (Nasdaq: ... and store adult stem cells, announced today it will report ... 2009, on Thursday, November 5, 2009. , ... host a conference call Thursday, November 5, 2009 at 2:00 ...
... , ROCKVILLE, Md., Oct 30 Novavax, Inc. (Nasdaq: ... third quarter financial results in a press release to be ... 2009. The Company will hold an investor conference call to ... Friday, November 6, 2009. The call will be hosted by ...
Cached Biology Technology:BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 2BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 3BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 4BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 5BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 6BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes 7Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009 2Novavax Announces Release Date of 2009 Third Quarter Financial Results and Investor Conference Call 2
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... The first real-world, demonstration-scale project in Nevada for ... stage of research at the University of Nevada, Reno. ... is an economical, commercially viable renewable energy source in ... outdoor cold-weather crop of algae as part of their ...
... TGen Clinical Research Services (TCRS) at Scottsdale Healthcare ... may offer broad potential to treat solid tumors. ... conducted at TGen Clinical Research Services at Scottsdale Healthcare, ... (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo ...
... bleaching is not only a con, but is dangerous to ... journal. The light treatment gives absolutely no benefit over ... four times as much as sunbathing, reports a study in ... match Tom Cruise,s glittering pearly-whites would be better off ignoring ...
Cached Biology News:Success for first outdoor, large-scale algae-to-biofuel research project in Nevada 2TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug 2
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
... Molecular Probes intensely fluorescent and ... potential for use in a variety ... deliver a strong signal. Unfortunately, protein- ... regions that may cause them to ...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
... licensed, high throughput, water bath thermal cycler capable ... microplates. This equates to 9,216 reactions per run ... rapidly transfers a basket of plates between three ... are considerably faster than those of peltier block ...
Biology Products: